Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05293184
Other study ID # RG-16-078-AM01
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 28, 2016
Est. completion date December 31, 2099

Study information

Verified date February 2024
Source Foundation for Angelman Syndrome Therapeutics, Australia
Contact Megan Tones, PhD
Email curator@angelmanregistry.info
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The Global Angelman Syndrome Registry is an online patient organisation driven registry to collect information about the natural history of children and adults with Angelman Syndrome. The registry will facilitate 1) recruitment for clinical trials into therapies and interventions to benefit participants with Angelman Syndrome and their families, and 2) advancement of research and best standards of care for Angelman Syndrome. The registry is currently available in English, Spanish, Traditional Chinese, Italian, Polish, Hindi, and Brazilian Portuguese.


Recruitment information / eligibility

Status Recruiting
Enrollment 5000
Est. completion date December 31, 2099
Est. primary completion date December 31, 2099
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Diagnosis of Angelman Syndrome Exclusion Criteria: -

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Observational study only


Locations

Country Name City State
Australia Queensland University of Technology Brisbane Queensland

Sponsors (2)

Lead Sponsor Collaborator
Foundation for Angelman Syndrome Therapeutics, Australia Queensland University of Technology

Country where clinical trial is conducted

Australia, 

References & Publications (7)

Leader G, Gilligan R, Whelan S, Coyne R, Caher A, White K, Traina I, Muchenje S, Machaka RL, Mannion A. Relationships between challenging behavior and gastrointestinal symptoms, sleep problems, and internalizing and externalizing symptoms in children and — View Citation

Leader G, Whelan S, Chonaill NN, Coyne R, Tones M, Heussler H, Bellgard M, Mannion A. Association between early and current gastro-intestinal symptoms and co-morbidities in children and adolescents with Angelman syndrome. J Intellect Disabil Res. 2022 Nov — View Citation

Napier KR, Tones M, Simons C, Heussler H, Hunter AA, Cross M, Bellgard MI. A web-based, patient driven registry for Angelman syndrome: the global Angelman syndrome registry. Orphanet J Rare Dis. 2017 Aug 1;12(1):134. doi: 10.1186/s13023-017-0686-1. — View Citation

Roche, L., Tones, M., Cross, M. et al. An Overview of the Adaptive Behaviour Profile in Young Children with Angelman Syndrome: Insights from the Global Angelman Syndrome Registry. Adv Neurodev Disord 6, 442-455 (2022). https://doi.org/10.1007/s41252-022-0

Roche, L., Tones, M., Williams, M.G. et al. Caregivers Report on the Pathway to a Formal Diagnosis of Angelman Syndrome: A Comparison Across Genetic Etiologies within the Global Angelman Syndrome Registry. Adv Neurodev Disord 5, 193-203 (2021). https://do

Tones M, Cross M, Simons C, Napier KR, Hunter A, Bellgard MI, Heussler H. Research protocol: The initiation, design and establishment of the Global Angelman Syndrome Registry. J Intellect Disabil Res. 2018 May;62(5):431-443. doi: 10.1111/jir.12482. — View Citation

Tones M, Zeps N, Wyborn Y, Smith A, Barrero RA, Heussler H, Cross M, McGree J, Bellgard M. Does the registry speak your language? A case study of the Global Angelman Syndrome Registry. Orphanet J Rare Dis. 2023 Oct 19;18(1):330. doi: 10.1186/s13023-023-02904-1. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Gather longitudinal data on individuals living with Angelman Syndrome Parent/ caregiver reporting on diagnosis, clinical status, and patient-reported outcomes of individual living with Angelman Syndrome. This will be achieved by inviting parents/ caregivers with additional questionnaire like modules, and tracking changes in their responses over time. 70 years (lifespan)
See also
  Status Clinical Trial Phase
Completed NCT00004351 - Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes N/A
Enrolling by invitation NCT06139172 - Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Recruiting NCT06229769 - Natural History Study for Patients With Angelman Syndrome
Enrolling by invitation NCT03836300 - Parent and Infant Inter(X)Action Intervention (PIXI) N/A
Completed NCT03235037 - Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome N/A
Recruiting NCT05100810 - Angelman Syndrome Natural History Study-FAST UK
Completed NCT03644693 - Nutritional Formulation for Angelman Syndrome N/A
Completed NCT03358823 - Study on the Brain Network of Angelman Syndrome
Recruiting NCT06337383 - Study of the Prevalence of Autistic Traits in Angelman Syndrome
Recruiting NCT05945576 - IDMet (RaDiCo Cohort) (RaDiCo-IDMet)
Completed NCT02670694 - Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW N/A
Recruiting NCT04768803 - Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity
Recruiting NCT05630066 - Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. Phase 2
Completed NCT00348933 - Dietary Supplements for the Treatment of Angelman Syndrome N/A
Recruiting NCT05011851 - An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome Phase 2
Terminated NCT03882918 - An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome Phase 3
Completed NCT02996305 - A Study in Adults and Adolescents With Angelman Syndrome (STARS) Phase 2
Completed NCT02056665 - Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome Phase 2
Completed NCT01281475 - A Trial of Levodopa in Angelman Syndrome Phase 2/Phase 3